Elekta and Royal Philips have inked a deal to deepen their existing partnership to advance comprehensive and personalized cancer care through precision oncology solutions. The extended collaboration builds on the two companies’ successful cooperation in the fast-emerging field of MR-guided adaptive radiation therapy. Through deeper cross-portfolio collaboration, Elekta and Philips will utilize their complementary capabilities to further improve patient care.
Benefiting Patients Throughout the Care Pathway
Oncology care is transforming, driven by an increasingly precise diagnosis of each tumor, and a continuously expanding range of therapy options. To fully capitalize on these opportunities, healthcare providers require integrated solutions throughout the entire cancer care pathway, from diagnosis to treatment and follow-up.
This integrated approach has the potential to provide:
- Quicker, more accurate visualization of the tumor
- Easier decision of optimal treatment strategy
- Earlier assessment of therapy response
- More effective and efficient therapy delivery
The strengthened partnership intends to further deliver a better experience in diagnosis and adaptive, personalized treatments for clinicians, shorter treatment times and more precise therapy for patients, and lowered costs of care for healthcare providers.
“I expect this extended partnership to unlock opportunities that will provide better outcomes for people with cancer,” says Gustaf Salford, Elekta’s president and CEO. “Together, we’ll combine advanced informatics and image-guided RT solutions to deliver greater precision in oncology. This means easier selection by clinicians of the optimal treatment strategy and more efficient and effective therapy delivery.”
“To capitalize on the opportunities presented by increasingly precise diagnosis and the fast-expanding range of therapies available for cancer patients, it’s essential to provide integrated systems and solutions that provide the right insights at the right time throughout each patient’s care journey,” adds Kees Wesdorp, chief business leader of precision diagnosis at Philips.
“By deepening our already-successful collaboration with Elekta, we will accelerate towards our goal of providing clear care pathways and predictable outcomes for every cancer patient,” Wesdorp says. “Today’s announcement is an important next step in the implementation of our strategy in precision diagnosis.”
In this preferred, although non-exclusive, partnership, Elekta and Philips will leverage their capabilities to pursue integrated vendor-agnostic solutions, enhancing interoperability between the two parties’ systems and software to drive precision in oncology.